Articles

The new U.S. healthcare law signed by President Obama today includes the Physician Payments Sunshine Act – and an important win for the survey and opinion research profession. Thanks to lobbying by the Marketing Research Association (MRA) and targeted outreach by MRA grassroots volunteers, the Sunshine Act excludes incentive payments for doctors who participate in marketing research projects.

The U.S. survey and research profession testified today before a joint hearing in the Minnesota House and Senate. The Marketing Research Association’s (MRA) Director of Government Affairs, Howard Fienberg, PLC, defended the use of physician incentives in pharmaceutical and medical device manufacturing.

Today, the Marketing Research Association (MRA) announces victory in its lobbying and grassroots actions to protect research with health care practitioners in Massachusetts. The Massachusetts Department of Health has issued official guidance exempting market research incentives from the application of the state’s new Marketing Code of Conduct for pharmaceutical and medical device manufacturers.

Recent regulations passed in Massachusetts will severely hurt research with healthcare practitioners. The Marketing Research Association (MRA) is calling for all members of the research profession in Massachusetts to take action now.

MRA scored several recent victories in the ongoing fight against legislation to require public reporting of survey research incentives for health care practitioners or that ban them outright. MRA recently helped to convince legislators in Maryland and Rhode Island to withdraw their bills and helped to defeat legislation in Mississippi.

The New Mexico State Senate recently defeated a bill which would have required the public reporting of incentives paid to health care professionals for participation in marketing research studies sponsored by pharmaceutical, medical device or medical supply manufacturers.

Pharmaceutical marketing research and data analytics companies should not be required to assume responsibility for formal reporting of adverse events (AEs) uncovered during routine pharmaceutical marketing research and data analytics in the U.S. because: